Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic L… (NCT00026351) | Clinical Trial Compass
CompletedPhase 2
Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
United StatesStarted 2000-12
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining pentostatin and rituximab in treating patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed low-grade non-Hodgkin's lymphoma
* REAL classification:
* B-cell chronic lymphocytic leukemia
* Prolymphocytic leukemia
* Small lymphocytic lymphoma
* Follicular center lymphoma (grade I, II, or III)
* Extranodal marginal zone B-cell lymphoma Malt type
* International Working Group classification:
* Small lymphocytic/chronic lymphocytic leukemia (CLL)
* CLL with lymph node involvement allowed
* Small lymphocytic plasmacytoid
* Follicular small cleaved cell
* Follicular mixed small and large cell
* Follicular predominantly large cell
* Measurable disease
* Lymph node more than 1 cm in longest transverse diameter NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low", "intermediate", or "high" grade lymphoma. However, this protocol uses the former terminology.
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* More than 6 months
Hematopoietic:
* Absolute neutrophil count at least 1,000/mm\^3
* Platelet count at least 75,000/mm\^3
* Hemoglobin at least 9 g/dL
Hepatic:
* Bilirubin no greater than 2.0 mg/dL
* AST no greater than 5 times upper limit of normal
Renal:
* Creatinine less than 2.0 mg/dL
* BUN normal
* Urinalysis normal
Cardiovascular:
* LVEF normal in patients with histo…